Last updated on June 2018

A Study to Evaluate the Pharmacokinetics Safety and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)


Brief description of study

To satisfy a postmarketing requirement, the sponsor has been requested to conduct a Phase 1/Phase 2 single-group clinical study to investigate the pharmacokinetics and preliminary safety and efficacy of omacetaxine following a fixed-dose administration to patients with CP or AP CML who have failed 2 or more tyrosine kinase inhibitor (TKI) therapies.

Clinical Study Identifier: NCT02078960

Contact Investigators or Research Sites near you

Start Over

Teva U.S. Medical Information

Teva Investigational Site 12550
Atlanta, GA United States

Teva U.S. Medical Information

Teva Investigational Site 12543
Indianapolis, IN United States

Teva U.S. Medical Information

Teva Investigational Site 12547
Buffalo, NY United States

Teva U.S. Medical Information

Teva Investigational Site 12546
Cincinnati, OH United States

Teva U.S. Medical Information

Teva Investigational Site 12544
Houston, TX United States

Teva U.S. Medical Information

Teva Investigational Site 37048
Gent, Belgium

Teva U.S. Medical Information

Teva Investigational Site 37047
Leuven, Belgium

Teva U.S. Medical Information

Teva Investigational Site 35157
Pierre Benite Cedex, France

Teva U.S. Medical Information

Teva Investigational Site 87029
Busan, Korea, Republic of

Teva U.S. Medical Information

Teva Investigational Site 87032
Busan, Korea, Republic of

Teva U.S. Medical Information

Teva Investigational Site 87033
Daegu-si, Korea, Republic of

Teva U.S. Medical Information

Teva Investigational Site 87028
Jeonju, Korea, Republic of

Teva U.S. Medical Information

Teva Investigational Site 87026
Seoul, Korea, Republic of

Teva U.S. Medical Information

Teva Investigational Site 87031
Seoul, Korea, Republic of

Teva U.S. Medical Information

Teva Investigational Site 87034
Suwon, Korea, Republic of

Teva U.S. Medical Information

Teva Investigational Site 87027
Ulsan, Korea, Republic of

Teva U.S. Medical Information

Teva Investigational Site 12545
Jacksonville, FL United States

Teva U.S. Medical Information

Teva Investigational Site 12549
Fairway, KS United States

Teva U.S. Medical Information

Teva Investigational Site 12548
Montreal, Canada

Teva U.S. Medical Information

Teva Investigational Site 35158
Grenoble, France

Teva U.S. Medical Information

Teva Investigational Site 87030
Gyeonggi-do, Korea, Republic of